NO20092535L - Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol - Google Patents

Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol

Info

Publication number
NO20092535L
NO20092535L NO20092535A NO20092535A NO20092535L NO 20092535 L NO20092535 L NO 20092535L NO 20092535 A NO20092535 A NO 20092535A NO 20092535 A NO20092535 A NO 20092535A NO 20092535 L NO20092535 L NO 20092535L
Authority
NO
Norway
Prior art keywords
alpha
beta
naphthalenyl
dimethylamino
bromo
Prior art date
Application number
NO20092535A
Other languages
English (en)
Other versions
NO342773B1 (no
Inventor
Sigrid Carl Maria Stokbroekx
Yolande Lydia Lang
Jean Francois Alexandre Lucas Hegyi
Wim Albert Alex Aelterman
Carina Leys
Peter Jozef Maria Van Remoortere
Anne Faure
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092535(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20092535L publication Critical patent/NO20092535L/no
Publication of NO342773B1 publication Critical patent/NO342773B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen angår fumaratsaltet av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol, farmasøytiske sammensetninger omfattende som aktiv ingrediens nevnte salt og fremgangsmåter for deres fremstilling.
NO20092535A 2006-12-05 2009-07-06 Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol NO342773B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (2)

Publication Number Publication Date
NO20092535L true NO20092535L (no) 2009-08-06
NO342773B1 NO342773B1 (no) 2018-08-06

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092535A NO342773B1 (no) 2006-12-05 2009-07-06 Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol

Country Status (34)

Country Link
US (1) US8546428B2 (no)
EP (1) EP2086940B1 (no)
JP (2) JP2010511663A (no)
KR (1) KR101514700B1 (no)
CN (2) CN105012303A (no)
AP (1) AP2498A (no)
AR (1) AR064149A1 (no)
AU (1) AU2007328945B2 (no)
BR (1) BRPI0719693A2 (no)
CA (1) CA2668512C (no)
CL (1) CL2007003472A1 (no)
CY (1) CY1113594T1 (no)
DK (1) DK2086940T3 (no)
EA (1) EA017091B9 (no)
ES (1) ES2387923T3 (no)
HK (1) HK1214513A1 (no)
HR (1) HRP20120639T1 (no)
IL (1) IL199077A (no)
JO (1) JO2973B1 (no)
ME (1) ME01456B (no)
MX (1) MX2009005909A (no)
MY (1) MY148844A (no)
NO (1) NO342773B1 (no)
NZ (1) NZ576485A (no)
PE (1) PE20081350A1 (no)
PL (1) PL2086940T3 (no)
PT (1) PT2086940E (no)
RS (1) RS52408B (no)
SI (1) SI2086940T1 (no)
TW (1) TWI417098B (no)
UA (1) UA97813C2 (no)
UY (1) UY30762A1 (no)
WO (1) WO2008068231A1 (no)
ZA (1) ZA200903907B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
KR102631986B1 (ko) * 2015-01-27 2024-01-30 얀센 파마슈티카 엔브이 분산성 조성물
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
KR102106318B1 (ko) * 2015-10-20 2020-05-06 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 베다퀼린 푸마레이트의 결정형 및 그의 제조방법
KR102359707B1 (ko) * 2016-07-20 2022-02-09 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
AU2018298855B2 (en) 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
CN122320982A (zh) 2019-01-09 2026-07-03 詹森药业有限公司 治疗非结核分枝杆菌疾病的组合
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
TW202233168A (zh) 2020-11-12 2022-09-01 比利時商健生藥品公司 治療非結核分枝桿菌疾病的藥物組分之組合
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
US5965572A (en) 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
CZ300261B6 (cs) * 1996-10-30 2009-04-01 Eli Lilly And Company Použití hydrochloridové soli raloxifenu pro prípravu léciva pro prevenci rakoviny prsu
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
SI1527050T1 (sl) * 2002-07-25 2010-08-31 Janssen Pharmaceutica Nv Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
MXPA06013888A (es) * 2004-05-28 2007-01-26 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos.
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
EA009779B1 (ru) * 2004-12-24 2008-04-28 Янссен Фармацевтика Н.В. Лечение латентного туберкулёза

Also Published As

Publication number Publication date
CA2668512A1 (en) 2008-06-12
EA017091B1 (ru) 2012-09-28
JO2973B1 (en) 2016-03-15
KR20090087020A (ko) 2009-08-14
HK1214513A1 (zh) 2016-07-29
CN105012303A (zh) 2015-11-04
AR064149A1 (es) 2009-03-18
EA017091B9 (ru) 2014-10-30
WO2008068231A1 (en) 2008-06-12
TWI417098B (zh) 2013-12-01
HRP20120639T1 (hr) 2012-08-31
ZA200903907B (en) 2013-08-28
PL2086940T3 (pl) 2012-10-31
JP2010511663A (ja) 2010-04-15
NO342773B1 (no) 2018-08-06
JP2015028049A (ja) 2015-02-12
UY30762A1 (es) 2008-07-03
MX2009005909A (es) 2009-06-16
US8546428B2 (en) 2013-10-01
TW200838527A (en) 2008-10-01
CN101547904A (zh) 2009-09-30
PT2086940E (pt) 2012-08-09
SI2086940T1 (sl) 2012-09-28
CA2668512C (en) 2015-03-24
PE20081350A1 (es) 2008-09-18
JP5894239B2 (ja) 2016-03-23
AU2007328945A1 (en) 2008-06-12
US20100028428A1 (en) 2010-02-04
UA97813C2 (uk) 2012-03-26
EP2086940A1 (en) 2009-08-12
EA200970532A1 (ru) 2009-10-30
KR101514700B1 (ko) 2015-04-24
CY1113594T1 (el) 2016-06-22
NZ576485A (en) 2012-01-12
ME01456B (me) 2014-04-20
AP2498A (en) 2012-10-19
CL2007003472A1 (es) 2008-08-22
ES2387923T3 (es) 2012-10-04
BRPI0719693A2 (pt) 2013-12-24
AP2009004870A0 (en) 2009-06-30
DK2086940T3 (da) 2012-08-20
AU2007328945B2 (en) 2014-04-03
MY148844A (en) 2013-06-14
EP2086940B1 (en) 2012-05-16
IL199077A (en) 2016-09-29
RS52408B (sr) 2013-02-28

Similar Documents

Publication Publication Date Title
EA017091B9 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
NO20090628L (no) Pyridizinon derivativater
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
NO20081844L (no) Terapeutiske forbindelser
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
UY30779A1 (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
NO20084852L (no) MGLUR5 modulatorer V
ATE520668T1 (de) Sigmarezeptor-inhibitoren
MY160018A (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
MY164864A (en) Indenone derivative and pharmaceutical composition comprising same
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
GEP20135998B (en) Heterocyclic sulfonamide derivatives
NO20073702L (no) Ikke-steroid glukocorticoid reseptor modulatorer
CO6290762A2 (es) Nuevos derivados quinazolin-2, 4-diona y una composicion farmaceutica para prevenir a tratar la enfermedad neurocerebral
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento